A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy

Clinical Oncology

Volumn 14, Issue 1, 2002, Pages 23-27

  Assersohn, L ^a   Sourberbielle, B E ^a,c   O'brien M E R ^a,b   Archer, C D ^a   Mendes, R ^a   Bass, R ^b   Bromelow, K V ^c   Palmer, R D ^d   Bouilloux, E ^e   Kennard, D A ^e   Smith, I E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MidKent Oncology Centre   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e Centre Point   (United Kingdom)

Author keywords

Chemotherapy; Lung cancer; Mycobacterium vaccae; Small cell; SRL172

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOMYCIN C; PLATINUM DERIVATIVE; SRL 172; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MALAISE; MALE; MUCOSA INFLAMMATION; MYCOBACTERIUM VACCAE; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0036464024     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.0030     Document Type: Article

References (10)

1. Treatment of small cell lung cancer patients
2. New chemotherapy agents for small cell lung cancer
3. Update on the treatment of small cell lung cancer (SCLC)
4. A highly active regimen for malignant mesothelioma with new biological data
5. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma
6. Long survival in 15 patients with small cell lung cancer (SCLC) immunized with BEC2 plus BCG after initial therapy: An update
7. Possible improved survival of patients with stage IVAJCC melanoma receiving SRL172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes
8. Immunotherapy of advanced prostate cancer: A phase I/II trial using Mycobacterium vaccae (SRL172)
9. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer
10. Randomized Phase III study or irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive disease small cell lung cancer: Japan Clinical Oncology Group study (JCOG9511)